Pfizer Supports Online Alzheimer's Disease Health Center
Pfizer Supports Online Alzheimer's Disease
Online health-content provider TheVisualMD has launched a new Web-based Alzheimer's Disease Health Center, which was funded by the Alzheimer's Immunotherapy Program (AIP) of Pfizer Inc. and Janssen Alzheimer Immunotherapy.
The AIP collaboration aims to deliver comprehensive and meaningful solutions to address the needs of people affected by Alzheimer's disease.
The Health Center initiative features a digital e-booklet, created with the support of leading researchers in the field, and covers key topics, including:
- How Alzheimer's disease impacts brain function;
- The differences in brain function in normal aging versus aging with Alzheimer's disease;
- The stages and pathophysiology of Alzheimer's disease; and
- Risk factors and potential prevention strategies.
TheVisual MD planned and developed the program and content, and the AIP reviewed it for accuracy. To access the digital e-booklet, click here.
"This project provides a rich, visual experience to learn and understand more about the causes, impact and risk factors of Alzheimer's disease," said George Migias, Senior Director, Commercial Development, Alzheimer's Immunotherapy Program-Bapineuzumab. "We hope that sharing key information about Alzheimer's disease in this cutting-edge format and forum will help people who are affected by this disease."
TheVisualMD.com is considered to be one of the world's largest libraries of high-resolution 3D scans of real human data. Its large collection of data is used to create visualizations using advanced 3D medical technologies.
Alzheimer's Disease International, a nonprofit organization, estimates that as many as 28 million of the world's 36 million people living with dementia are undiagnosed and do not have access to treatment, information and care.